Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Columbus, Ohio 43210


The purpose of this study is to determine whether green tea may lower the risk of certain cancers.

Study summary:

Green tea contains phytochemicals, especially flavonoids. Phytochemicals are not absolutely required for normal functions, but may confer health benefits such as antioxidant actions. One can live without phytochemicals, but one may live longer and better with them. The phytochemicals in tea have been proposed to inhibit cancer onset via several different mechanisms. An obvious question is: Can anti-cancer actions of green tea be duplicated by black tea, which in the USA, is consumed more than green tea? The question remains unanswered, and will not be addressed by this project since many questions about green tea have not been answered yet. The contents of both type teas overlap in flavonoids, but green tea has more of the agents thought to be most effective. For example, some of the research cited below uses the flavonoid epigallocatechin gallate. Green tea has 5 times more of this flavonoid than black tea. This study has two purposes. First, a case will be made that green tea may have several anti-cancer mechanisms, but this contention is not well confirmed by human intervention studies. This case will be made by addressing four questions. Second, justification will be given for the choice of mechanisms to be examined in this project's human intervention.


Inclusion Criteria: - Healthy 23-40 year old males and non-pregnant females, who are moderately heavy smokers (1-1.75 packs/day, > 2 years) Exclusion Criteria: - Habitual tea intake - Habitual flavonoid supplementation - Soy product intake over twice a week (soy is high in flavonoids). - Pulmonary diseases - Chronic or acute infection - Admission of heavy alcohol intake (> 14 beers or drinks a week) - Body mass index (BMI) > 30 (moderately overweight subjects will be taken) - Abnormal EKG - History of heart or other major health problems (ie arthritis, diabetes). - Subjects with slightly high blood pressure will be eligible for the project, but more severe hypertension (>150/100)



Primary Contact:

Principal Investigator
Philip Diaz, M.D.
Ohio State University

Backup Contact:


Location Contact:

Columbus, Ohio 43210
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.